Skip to content

Yew Bio-Pharm Group, Inc.

CIK 0001548240

← back to feed
Revenue (TTM)
$34.05M
−2.1% YoY Q3 Nov 2021
Net Income (TTM)
$1.82M
+48.6% YoY Q3 Nov 2021
EPS Diluted (TTM)
$0.08
+100.0% YoY Q3 Nov 2021
Gross Margin
4.2%
Q3 Nov 2021
Operating Margin
7.3%
Q3 Nov 2021
Net Margin
5.3%
Q3 Nov 2021
Free Cash Flow (TTM)
$13.31M
Q3 Nov 2021
Cash
$28.45K
Q3 Nov 2021
Total Debt
$9.01M
Q3 Nov 2021
Shares Outstanding
51.7M sh
Q3 Nov 2021

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings